Gertz MA. Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol. 2021;96(2):258–69.

Article  PubMed  Google Scholar 

Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L, et al. Waldenstrom macroglobulinemia: review of pathogenesis and management. Clin Lymphoma Myeloma Leuk. 2017;17(5):252–62.

Article  PubMed  PubMed Central  Google Scholar 

Ravi G, Kapoor P. Current approach to Waldenstrom macroglobulinemia. Cancer Treat Res Commun. 2022;31: 100527.

Article  PubMed  Google Scholar 

Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522–8.

Article  CAS  PubMed  Google Scholar 

Buske C, Jurczak W, Salem JE et al. Managing Waldenström’s macroglobulinemia with BTK inhibitors. Leukemia. 2023;37:35–46.

Lin L, Czerwinski R, Kelleher K, Siegel MM, Wu P, Kriz R, et al. Activation loop phosphorylation modulates Bruton’s tyrosine kinase (Btk) kinase domain activity. Biochemistry. 2009;48(9):2021–32.

Article  CAS  PubMed  Google Scholar 

Tasso B, Spallarossa A, Russo E, Brullo C. The development of BTK inhibitors: a five-year update. Molecules. 2021;26(23):7411.

•• Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94. First study to show the promise of a new class of drugs, BTK inhibitors in WM.

•• Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–40. Pivitol phase 2 trial that led to the approval of ibrutinib, first-in-class, BTK inhibitor in WM.

Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2021;39(6):565–75.

Article  CAS  PubMed  Google Scholar 

•• Dimopoulos MA, Tedeschi A, Trotman J, Garcia-Sanz R, Macdonald D, Leblond V, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom’s macroglobulinemia. N Engl J Med. 2018;378(25):2399–410. Regulatory phase 3 trial that led to the approval of ibrutinib, first-in-class BTK inhibitor (in combination with rituximab) in WM.

•• Tam CS, Opat S, D’Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–50. ASPEN study is the first head-to-head study comparing 2 BTKi in WM. This regulatory randomized phase 3 trial that compared zanubrutinib, a next-generation BTKi with ibrutinib, first-in-class BTK inhibitor in WM and led to the approval of zanubrutinib due to its similar efficacy and superior safety profile.

Dimopoulos M, Opat S, D’Sa S, Jurczak W, Lee HP, Cull G, et al. P1161: ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (Zanu) vs ibrutinib (IBR) in patients (PTS) with Waldenstrom macroglobulinemia (WM). HemaSphere. 2022;6.

•• Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020;4(23):6009–18. ASPEN single arm sub-study to show good activity of zanubrutinib, a next-generation BTKi, in patients with MYD88WT. This subpopulation does not typically respond well to ibrutinib.

Tam CS, Opat S, D’Sa SP, Jurczak W, Lee H-P, Cull G, et al. Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenström macroglobulinemia. Blood Advances. 2024:bloodadvances.2023010906.

• Owen RG, McCarthy H, Rule S, D’Sa S, Thomas SK, Tournilhac O, et al. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7(2):e112–21. Phase 2 trial that showed efficacy and activity of next-generation covalent BTK inhibitor, acalabrutinib, in WM.

Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Berinstein N, Roos K, Mangoff K, Jiang Y, Klein G, McClure R, et al. Indolent lymphoma: high CR and VGPR rate with fixed duration bendamustine, rituximab and acalabrutinib in Waldenstroms macroglobulinaemia (BRAWM). Blood. 2023;142:3037. Ongoing phase 2 trial, with preliminary data showing high efficacy of a regimen using a standard chemoimmunotherapy (BR) backbone in conjunction with a covalent BTK inhibitor, acalabrutinib, for fixed duration in WM.

• Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019;133(4):299–305. Multi-center study demonstrating the efficacy of BTKi therapy for patients with Bing-Neel syndrome.

Wong J, Cher L, Griffiths J, Cohen A, Huang J, Wang L, et al. Efficacy of zanubrutinib in the treatment of Bing–Neel syndrome. HemaSphere. 2018;2(6):e155.

Cheah CY, Wickham N, Yannakou CK, Lewis KL, Hui C-H, Tang PS, et al. Phase 1 study of TG-1701, a selective irreversible inhibitor of Bruton’s tyrosine kinase (BTK), in patients with relapsed/refractory B-cell malignancies. Blood. 2019;134(Supplement_1):4001.

Article  Google Scholar 

• Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom’s macroglobulinemia. Cancer Sci. 2020;111(9):3327–37. Single-arm, phase 2 trial that showed efficacy and activity of tirabrutinib, a next-generation covalent BTK inhibitor, in WM.

• Cao XX, Jin J, Fu CC, Yi SH, Zhao WL, Sun ZM, et al. Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstro’s macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study. EClinicalMedicine. 2022;52:101682. A phase 2 study investigating the next-generation covalent BTKi, orelabrutinib, showing promising results in R/R WM.

Cao X, Jin J, Cheng Cheng F, Yi S, Zhao W, Sun Z, et al. Orelabrutinib monotherapy in patients with relapsed or refractory Waldenström’s macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study: long term follow-up results. Blood. 2023;142:3039.

Article  Google Scholar 

• Woyach JA, Flinn IW, Awan FT, Eradat H, Brander D, Tees M, et al. Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated bruton tyrosine kinase inhibitor for B-cell malignancies: updated analysis of the open-label phase 1/2 dose-expansion BELLWAVE-001 study. Blood. 2022;140(Supplement 1):7004–6. A study assessing the safety and activity of nemtabrutinib, a non-covalent BTK inhibitor in B-cell malignancies, including WM.

•• Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. The Lancet. 2021;397(10277):892–901. A study showing safety and activity of pirtobrutinib, a non-covalent reversible BTK inhibitor in B-cell malignancies, including patients with WM who have been previously exposed to covalent BTK inhibitors.

•• Palomba ML, Patel MR, Eyre TA, Jurczak W, Lewis DJ, Gastinne T, et al. Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK Inhibitor in relapsed/refractory Waldenström macroglobulinemia: results from the phase 1/2 BRUIN study. Blood. 2022;140(Supplement 1):557–60. A sub-study of the BRUIN trial showing activity of pirtobrutinib, a non-covalent BTK inhibitor in WM, including patients previously exposed to covalent BTK inhibitors.

Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14(7):417–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609–17.

Article  CAS  PubMed  Google Scholar 

Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA. Treatment of relapsed or refractory Waldenstrom’s macroglobulinemia with bortezomib. Haematologica. 2005;90(12):1655–8.

CAS  PubMed  Google Scholar 

Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570–5.

Article  CAS  PubMed  Google Scholar 

Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. J Clin Oncol. 2009;27(23):3830–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276–82.

Article  CAS  PubMed  Google Scholar 

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–40.

Article  PubMed  Google Scholar 

Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383–91.

Article  CAS  PubMed  Google Scholar 

Groen K, van de Donk N, Stege C, Zweegman S, Nijhof IS. Carfilzomib for relapsed and refractory multiple myeloma. Cancer Manag Res. 2019;11:2663–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom’s macroglobulinemia. Blood. 2014;124(4):503–10.

Article  CAS  PubMed  Google Scholar 

Ghobrial IM, Vij R, Siegel D, Badros A, Kaufman J, Raje N, et al. A phase Ib/II study of oprozomib in patients with advanced multiple myeloma and Waldenström macroglobulinemia. Clin Cancer Res. 2019;25(16):4907–16.

Article  CAS  PubMed  Google Scholar 

Castillo JJ, Meid K, Flynn CA, Chen J, Demos MG, Guerrera ML, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up. Blood Adv. 2020;4(16):3952–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Castillo JJ, Meid K, Gustine JN, Dubeau T, Severns P, Hunter ZR, et al. Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenstrom macroglobulinemia. Clin Cancer Res. 2018;24(14):3247–52. A study showing activity of an oral proteasome inhibitor (ixazomib)-based regimen in patients with treatment-naïve WM.

• Kersten MJ, Amaador K, Minnema MC, Vos JMI, Nasserinejad K, Kap M, et al. Combining ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenström’s macroglobulinemia: final analysis of the phase I/II HOVON124/ECWM-R2 study. Journal of Clinical Oncology. 2021;40(1):40–51. A trial showing activity of an oral proteasome inhibitor (ixazomib) and subcutaneous rituximab-based regimen in patients with relapsed or refractory WM.

Ailawadhi S, Parrondo RD, Laplant B, Alegria VR, Elliott JB, Zimmerman A, et al. Phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinemia (WM). Blood. 2022;140(Supplement 1):9331–2.

Article  Google Scholar 

Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011;11(3):254–84.

Article  CAS  PubMed  PubMed Central